These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 7920209

  • 1. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
    Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T.
    Cancer Epidemiol Biomarkers Prev; 1994; 3(5):413-21. PubMed ID: 7920209
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
    Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF.
    Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
    [Abstract] [Full Text] [Related]

  • 4. Human cytochrome P4501A2.
    Landi MT, Sinha R, Lang NP, Kadlubar FF.
    IARC Sci Publ; 1999 Jun; (148):173-95. PubMed ID: 10493258
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
    Tang BK, Zhou Y, Kadar D, Kalow W.
    Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691
    [Abstract] [Full Text] [Related]

  • 7. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
    Denaro CP, Wilson M, Jacob P, Benowitz NL.
    Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
    Vincent-Viry M, Pontes ZB, Gueguen R, Galteau MM, Siest G.
    Genet Epidemiol; 1994 Mar; 11(2):115-29. PubMed ID: 8013893
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers.
    Pavanello S, Simioli P, Lupi S, Gregorio P, Clonfero E.
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):998-1003. PubMed ID: 12376499
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B, Sáenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, Mayayo E.
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.